Literature DB >> 18195598

Comparison of the effects of desmethylimipramine on behavior in the forced swim test in peripubertal and adult rats.

Robert N Pechnick1, Catherine J Bresee, Charlene M Manalo, Russell E Poland.   

Abstract

Although there are similarities in the clinical presentation of adolescent and adult depression, there are differences in the biological correlates and the responses to pharmacologic treatment. Selective serotonin reuptake inhibitor-type antidepressants are efficacious, but tricyclic antidepressants have no or limited efficacy in treating adolescent patients. The forced swim test (FST) is a widely accepted animal model used to screen drugs for antidepressant activity. It is not known whether tricyclic antidepressants produce differential effects in peripubertal and adult rats, as is found in adolescent and adult humans. The objective of the study was to test the hypothesis that the tricyclic antidepressant desmethylimipramine (DMI) would show efficacy in the FST in adult, but not in peripubertal, rats. Thirty-day-old (peripubertal) and 112-day-old (young adult) rats were pretreated with saline or DMI and subjected to the FST. DMI reduced the amount of floating behavior and increased the amount of climbing behavior in both peripubertal and adult rats. Thus, the tricyclic antidepressant DMI has antidepressant-like activity in peripubertal rats in the FST. Owing to the discrepancy between the preclinical and clinical data, the predictive validity of the FST might need to be reevaluated across different age groups.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18195598      PMCID: PMC2741497          DOI: 10.1097/FBP.0b013e3282f3d07f

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  20 in total

Review 1.  Assessing antidepressant activity in rodents: recent developments and future needs.

Authors:  John F Cryan; Athina Markou; Irwin Lucki
Journal:  Trends Pharmacol Sci       Date:  2002-05       Impact factor: 14.819

2.  Noradrenergic and serotonergic neuroendocrine responses in prepubertal, peripubertal, and postpubertal rats pretreated with desipramine and sertraline.

Authors:  Normand J Carrey; Serdar Dursun; Robert Clements; Ken Renton; Dan Waschbusch; Frank P MacMaster
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-08       Impact factor: 8.829

Review 3.  Mood disorders in children and adolescents: an epidemiologic perspective.

Authors:  R C Kessler; S Avenevoli; K Ries Merikangas
Journal:  Biol Psychiatry       Date:  2001-06-15       Impact factor: 13.382

Review 4.  Are child-, adolescent-, and adult-onset depression one and the same disorder?

Authors:  J Kaufman; A Martin; R A King; D Charney
Journal:  Biol Psychiatry       Date:  2001-06-15       Impact factor: 13.382

5.  Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial.

Authors:  M B Keller; N D Ryan; M Strober; R G Klein; S P Kutcher; B Birmaher; O R Hagino; H Koplewicz; G A Carlson; G N Clarke; G J Emslie; D Feinberg; B Geller; V Kusumakar; G Papatheodorou; W H Sack; M Sweeney; K D Wagner; E B Weller; N C Winters; R Oakes; J P McCafferty
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-07       Impact factor: 8.829

6.  Appropriate dosing regimens for treating juvenile rats with desipramine for neuropharmacological and behavioral studies.

Authors:  Megan E Kozisek; Jean D Deupree; William J Burke; David B Bylund
Journal:  J Neurosci Methods       Date:  2007-02-22       Impact factor: 2.390

7.  Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood.

Authors:  G H Moll; C Mehnert; M Wicker; N Bock; A Rothenberger; E Rüther; G Huether
Journal:  Brain Res Dev Brain Res       Date:  2000-02-07

8.  Antidepressant-like effects of aniracetam in aged rats and its mode of action.

Authors:  K Nakamura; Y Tanaka
Journal:  Psychopharmacology (Berl)       Date:  2001-11       Impact factor: 4.530

Review 9.  Tricyclic drugs for depression in children and adolescents.

Authors:  P Hazell; D O'Connell; D Heathcote; D Henry
Journal:  Cochrane Database Syst Rev       Date:  2002

10.  Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials.

Authors:  Karen Dineen Wagner; Paul Ambrosini; Moira Rynn; Christopher Wohlberg; Ruoyong Yang; Michael S Greenbaum; Ann Childress; Craig Donnelly; Deborah Deas
Journal:  JAMA       Date:  2003-08-27       Impact factor: 56.272

View more
  5 in total

1.  Effects of neonatal flutamide treatment on hippocampal neurogenesis and synaptogenesis correlate with depression-like behaviors in preadolescent male rats.

Authors:  J M Zhang; L Tonelli; W T Regenold; M M McCarthy
Journal:  Neuroscience       Date:  2010-04-21       Impact factor: 3.590

Review 2.  Ontogeny and regulation of the serotonin transporter: providing insights into human disorders.

Authors:  Lynette C Daws; Georgianna G Gould
Journal:  Pharmacol Ther       Date:  2011-04-05       Impact factor: 12.310

3.  Ontogeny of Norepinephrine Transporter Expression and Antidepressant-Like Response to Desipramine in Wild-Type and Serotonin Transporter Mutant Mice.

Authors:  Nathan C Mitchell; Melodi A Bowman; Georgianna G Gould; Wouter Koek; Lynette C Daws
Journal:  J Pharmacol Exp Ther       Date:  2016-11-09       Impact factor: 4.030

4.  Targeting Serotonin Transporters in the Treatment of Juvenile and Adolescent Depression.

Authors:  Melodi A Bowman; Lynette C Daws
Journal:  Front Neurosci       Date:  2019-02-27       Impact factor: 4.677

5.  Antidepressant-like drug effects in juvenile and adolescent mice in the tail suspension test: Relationship with hippocampal serotonin and norepinephrine transporter expression and function.

Authors:  Nathan C Mitchell; Georgianna G Gould; Corey M Smolik; Wouter Koek; Lynette C Daws
Journal:  Front Pharmacol       Date:  2013-10-28       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.